Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13. Armata focuses on developing bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Their pipeline includes candidates for pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, and they collaborate with Merck on synthetic phage candidates targeting an undisclosed infectious disease.
Details
News Market Reaction – ARMP
The recorded move for ARMP in the trading session of this news was +3.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
The presentation will be available on-demand starting at 7:00 AM ET on September 13, 2021. If you are an institutional or retail investor, and would like to listen to the Company's presentation, click HERE for the conference.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Media Contacts:
At Armata:
Steve Martin
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
858-800-2492
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-23rd-annual-global-investment-conference-301371143.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.